CYNTHIA BROWN

Issues related to legislation governing regulation of prediction markets.

Issues related to the 340B Drug Pricing Program.

Issues related to the 340B Drug Pricing Program.

Issues related to labor requirements and privacy/data collection; Issues related to joint employer rule.

Issues related to privacy/data collection; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).

Issues related to labor requirements and privacy/data collection; Issues related to Inflation Reduction Act of 2022 (PL 117-169).

Issues related to accelerated use of AMT credits; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to the Research and Development Tax Credit; Issues related to expensing.

Issues related to accelerated depreciation; Issues related to infrastructure deployment; Issues related to Research and Development Tax Credit; Issues related to Tax Cuts and Jobs Act (PL 115-97) Extension.

Issues related to spectrum auctions, infrastructure deployment, privacy, and 5G deployment; Issues related to National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).

Issues related to regulations that would restrict operations of farm bureau health insurance plans.

Issues related to space launch competition in the National Security Space (NSS) programs; Issues regarding civil space programs; Issues pertaining to NASA Reauthorization and commercial spaceflight; Issues related to the implementation of the CHIPS and Science Act of 2022 (PL 117-167).

Issues related to FAA launch approval.

Issues related to satellites.

Issues related to hospital reimbursement.

Issues related to hospital reimbursement.

Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.

Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.

Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.

Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.

Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.

Issues related to the implementation of the 45X tax credit; Issues related to cybersecurity and enhanced energy infrastructure.

Issues related to the implementation of the 45X tax credit; Issues related to the One Big Beautiful Bill Act (P.L. 119-21).

Issues related to the implementation of the 45X tax credit; Issues related to the One Big Beautiful Bill Act (P.L. 119-21).

Issues related to rural broadband coverage; Issues related to Rural Utilities Service Broadband; Issues related to privacy; Issues related to broadband mapping.

Issues related to infrastructure; Issues related to broadband.

Issues related to cyber intelligence.

Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines.

Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers.

Issues related to Orphan Drug Tax Credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.

Issues related to Defense, Transportation, and Science Authorization & Appropriations; Issues related to FAA re-authorization.

Issues related to Defense, Transportation, and Science Authorization & Appropriations; Issues related to FAA re-authorization.

Issues related to Defense, Transportation, and Science Authorization & Appropriations; Issues related to FAA re-authorization.

Issues related to safety standards for ROVs.

Issues related to international trade and tariff policies.

Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (PL 119-21).

Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).

Issues related to the implementation of the One Big Beautiful Bill Act (PL 119-21); Issues related to transmission.

Issues related to the implementation of the One Big Beautiful Bill Act (PL 119-21); Issues related to transmission.

Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.

Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.

Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.

Issues related to book minimum tax in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21)

Issues related to affordability, transmission policy and workforce development; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to transmission.

Issues related to affordability, transmission policy and workforce development; Issues related to transmission.

Issues related to autonomous vehicles, in general; Issues related to connected vehicles, in general; Issues related to privacy, in general; Issues related to vehicle safety, in general; Issues related to the One Big Beautiful Bill Act (P.L. 119-21), Corporate, International and Clean Energy Tax Provisions; Issues related to EV fees; Issues related to AI and Spectrum provisions. Issues related to H.R. 8870 - BUILDAmerica250Act.

Issues related to electric vehicle (EV) infrastructure, in general; The Infrastructure Investment and Jobs Act (PL 117-58), Implementation of issues related to climate and electrification provisions, Climate title; Issues related to implementation of clean energy and electrification provisions and international and corporate tax provisions in relation to the Inflation Reduction Act of 2022 (PL 117-169); Clean energy and electrification provisions and corporate and international tax provisions; Autonomous Vehicles in general; Connected Vehicles in general; Issues related to critical minerals; Issues related to FAA Reauthorization Act of 2024 (PL 118-63), in general; S. 161 - She DRIVES Act; Standard for All-Terrain Vehicles.; Issues related to the One Big Beautiful Bill Act (P.L. 119-21), Corporate, International and Clean Energy Tax Provisions; Issues related to EV fees; Issues related to AI and Spectrum provisions; Issues related to Section 232 Critical Mineral Tariff Investigation; Issues related to Section 232 Semiconductor Tariff Investigation; Issues related to Rare Earth Elements (REE). Issues related to transportation reauthorization bill. Issues related to H.R. 8870 - BUILDAmerica250Act.

Issues related to cybersecurity, spectrum legislation; Issues related to privacy; Issues related to supply chain.

Issues related to spectrum; Issues related to privacy; Issues related to supply chain; Issues related to spectrum in the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).

Issues related to privacy; Issues related to supply chain.

Issues affecting the gaming industry.

Issues related to preserving economic balance regarding regulation of the railroad industry; Issues related to two-man crew sites; Issues related to infrastructure and transportation; Issues related to safety requirements for rail carriers and trains transporting hazardous materials; Issues related to H.R. 2853/S. 1404 - Combating Organized Retail Crime Act of 2025.

Issues related to the implementation of the Infrastructure Investment and Jobs Act (PL 117-58); Issues related to the implementation of the CHIPS Act (PL 117-167).

Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.

Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.

Issues related to teaching hospitals; Issues related to hospital reimbursement.

Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Issues related to healthcare; Issues related to provider reimbursement.

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).

Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167); Issues related to AI.

Issues related to advanced design tax credit; Issues related to H.R. 802 - STAR Act of 2025; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167); Issues related to research and development tax amortization fix.

Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167); Issues related to export controls.

Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters"; Issues related to H.R. 4721/S. 2436 - Healthy H2O Act.

Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to appliance standards & EPCA reform in H.R. 4626 - Home Appliance Protection and Affordability Act.

Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.

Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.

Issues related to sports.

Issues related to the funding of the District of Columbia.

Issues related to chemical manufacturing.

Issues related to life sciences, laboratory and chemical manufacturing.

Issues related to domestic and international trade and tariff policies.

Issues related to EVTOL funding in the Department of Defense; Issues related to defense funding, servicemember quality of life, and technology upgrades.

DOD appropriations issues; Issues related to implementation of FAA Reauthorization Act of 2024 (PL 118-63); Issues related to Surface Transportation Reauthorization.

Issues related to the implementation of the Infrastructure Investment and Jobs Act (PL 117-58).

Issues related to artificial intelligence and education.

Issues related to funding for Title I programs; Issues related to Title I and digital education programs.

Issues related to digital learning in K-12 education, student privacy, and digital education; Issues related to funding for Title 1 programs.

Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.

Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).

Issues related to FEMA emergency transport response.

Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.

Issues related to healthcare data; Issues related to provider reimbursement.

Issues related to Medicare Advantage; Issues related to physician payments.

Issues related to wildfire related appropriations bills.

Issues related to wildfire related appropriations bills.

Issues related to wildfire related appropriations bills.

Issues related to Farm Bill Reauthorization; Issues related to the reintroduction of the Timber Innovation for Building Rural Communities Act (TIBRC) / 2026 Agriculture Appropriations; Issues related to Defense and Interior Appropriations; Issues related to extension of provisions in the Tax Cuts and Jobs Act (TCJA) (P.L. 115-97).

Issues related to Farm Bill Reauthorization; Issues related to the reintroduction of the Timber Innovation for Building Rural Communities Act (TIBRC) / 2026 Agriculture Appropriations; Issues related to Defense and Interior Appropriations; Issues related to extension of provisions in the Tax Cuts and Jobs Act (TCJA) (P.L. 115-97).

Issues related to beer excise tax.

Issues related to beer excise tax.

Issues related to permitting, affordability, and reliability.

Issues related to permitting, affordability, and reliability.

Issues related to permitting, affordability, and reliability.

Issues related to the 340B Drug Pricing Program.

Issues related to the 340B Drug Pricing Program.

Issues related to the implementation of the 45X tax credit; Issues related to cybersecurity and enhanced energy infrastructure.

Issues related to the implementation of the 45X tax credit; Issues related to the One Big Beautiful Bill Act (P.L. 119-21).

Issues related to the implementation of the 45X tax credit; Issues related to the One Big Beautiful Bill Act (P.L. 119-21).

Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (PL 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to flu and RSV vaccines.

Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Section 340B of the Public Health Service Act (PL 78-410); Issues related to pharmacy benefit managers.

Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.

Issues related to preserving economic balance regarding regulation of the railroad industry; Issues related to two-man crew sites; Issues related to infrastructure and transportation; Issues related to safety requirements for rail carriers and trains transporting hazardous materials; Issues related to H.R. 2853/S. 1404 - Combating Organized Retail Crime Act.

Issues related to the implementation of the Infrastructure Investment and Jobs Act (PL 117-58); Issues related to the implementation of the CHIPS Act (PL 117-167).

Issues related to Defense, Transportation, and Science Authorization & Appropriations; Issues related to FAA re-authorization; Issues related to Energy and Water appropriations related to indirect costs.

Issues related to Defense, Transportation, and Science Authorization & Appropriations; Issues related to FAA re-authorization.

Issues related to Defense, Transportation, and Science Authorization & Appropriations; Issues related to FAA re-authorization.

Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.

Issues related to teaching hospitals; Issues related to hospital reimbursement.

Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.

Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Issues related to safety standards for ROVs.

Issues related to international trade and tariff policies.

Issues related to healthcare; Issues related to provider reimbursement.

Issues related to accelerated use of AMT credits; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to the Research and Development tax credit; Issues related to expensing.

Issues related to the implementation of the One Big Beautiful Bill Act (PL 119-21); Issues related to transmission.

Issues related to the implementation of the One Big Beautiful Bill Act (PL 119-21); Issues related to transmission.

Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.

Issues related to regulations that would restrict operations of farm bureau health insurance plans.

Issues related to funding for Title I programs; Issues related to Title I and digital education programs.

Issues related to digital learning in K-12 education, student privacy, and digital education; Issues related to funding for Title 1 programs.

Issues related to artificial intelligence and education.

Issues related to hospital reimbursement.

Issues related to hospital reimbursement.

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Issues related to Farm Bill Reauthorization; Issues related to the reintroduction of the Timber Innovation for Building Rural Communities Act (TIBRC) / 2026 Agriculture Appropriations; Issues related to Defense and Interior Appropriations; Issues related to extension of provisions in the Tax Cuts and Jobs Act (TCJA) (P.L. 115-97).

Issues related to Farm Bill Reauthorization; Issues related to the reintroduction of the Timber Innovation for Building Rural Communities Act (TIBRC) / 2026 Agriculture Appropriations; Issues related to Defense and Interior Appropriations; Issues related to extension of provisions in the Tax Cuts and Jobs Act (TCJA) (P.L. 115-97).

Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.

Issues related to corporate tax, net operating loss, EBITA/EBIDA.

Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.

Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.

Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).

Issues related to FEMA emergency transport response.

Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.

Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to supply chain; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167).

Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to implementation of the CHIPS and Science Act of 2022 (PL 117-167); Issues related to AI.

Issues related to the semiconductor industry; Issues related to trade; Issues related to manufacturing; Issues related to AI; Issues related to H.R. 5885/S. 3150 - GAIN AI Act of 2025.

Issues related to financial services and tax.

Issues related to healthcare data; Issues related to provider reimbursement.

Issues related to Medicare Advantage; Issues related to physician payments.

Issues related to cybersecurity, spectrum legislation; Issues related to privacy; Issues related to supply chain.

Issues related to broadband spectrum policy, 5G deployment, rural broadband, and privacy; Issues related to supply chain; Issues related to privacy.

Issues related to spectrum; Issues related to privacy; Issues related to supply chain; Issues related to spectrum in the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).

Issues related to permitting, affordability, and reliability.

Issues related to permitting, affordability, and reliability.

Issues related to permitting, affordability, and reliability.

Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act; Issues related to the forthcoming CY 2027 Physician Fee Schedule Proposed Rule regarding possible establishment of a national reimbursement structure for proton beam therapy treatment.

Issues pertaining to veterans' access to proton therapy.

Issues related to the reimbursement in Medicare and Medicaid for providers of proton beam therapy; Issues related to H.R. 2120/S. 1031 - Radiation Oncology Case Rate (ROCR) Value-Based Program Act.

Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs and other China issues.

Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters"; Issues related to H.R. 4721/S. 2436 - Healthy H2O Act.

Issues affecting the gaming industry.

Issues related to sports.

Issues related to the funding of the District of Columbia.

Issues related to privacy/data collection; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).

Issues related to labor requirements and privacy/data collection; Issues related to Inflation Reduction Act of 2022 (PL 117-169).

Issues related to labor requirements and privacy/data collection; Issues related to food pricing.

Issues related to spectrum auctions, infrastructure deployment, privacy, and 5G deployment. Issues related to National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).

Issues related to accelerated depreciation; Issues related to infrastructure deployment; Issues related to Research and Development Tax Credit; Issues related to Tax Cuts and Jobs Act (PL 115-97) Extension.

Issues related to chemical manufacturing.

Issues related to domestic and international trade and tariff policies.

Issues related to life sciences, laboratory and chemical manufacturing.

Issues related to satellites.

Issues related to space launch competition in the National Security Space Program; Issues regarding civil space programs.

Issues related to FAA launch approval.

Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.

Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.

Issues related to EVTOL funding in the Department of Defense; Issues related to defense funding, servicemember quality of life, and technology upgrades; Issues related to Fiscal Year 2027 National Defense Authorization Act and Fiscal Year 2027 Appropriations.

Issues related to the implementation of the Infrastructure Investment and Jobs Act (PL 117-58).

DOD appropriations issues; Issues related to implementation of FAA Reauthorization Act of 2024 (PL 118-63); Issues related to Surface Transportation Reauthorization.

Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.

Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.

Issues related to infrastructure; Issues related to broadband.

Issues related to cyber intelligence.

Issues related to rural broadband coverage; Issues related to Rural Utilities Service Broadband; Issues related to privacy; Issues related to broadband mapping.

Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.

Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.

Issues related to the 340B Drug Pricing Program.

Intellectual property and process patent related issues.

Issues related to affordability, transmission policy and workforce development; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to transmission.

Issues related to book minimum tax in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (P.L. 119-21)

Issues related to affordability, transmission policy and workforce development; Issues related to transmission.

Issues regarding implementation of electric vehicle tax credits (30B and 30D) and alternative fuel infrastructure tax credit (30C); Issues pertaining to implementation of EV tax credits, implementation of clean energy and electrification provisions and corporate and international tax provisions; Issues related to implementation of clean energy and electrification provisions and international and corporate tax provisions in relation to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21), Corporate, International and Clean Energy Tax Provisions; Issues related to EV fees; Issues related to AI and Spectrum provisions; S. 1605 - International Competition for American Jobs Act. Issues related to H.R. 8870 - BUILDAmerica250Act.

Issues regarding patents, in general; Issues related to Standard Essential Patents; Issues related to vehicle data, specifically the Vehicle Data Access Caucus; Issues related to data privacy; Issues related to H.R. 1566/S. 1379 - REPAIR Act. Issues related to H.R. 8870 - BUILDAmerica250Act.

Issues related to safety and security surrounding Venues.

Issues related to transparency and accounting related to ticket sales pricing; Issues related to competition enforcement.

Issues related to transparency and accountability to ticket sales pricing.

Issues related to legislation governing regulation of prediction markets.

Issues related to anti-trust.

Issues related to payment for healthcare services; Issues related to healthcare data transparency.

Issues pertaining to payment for healthcare services and healthcare data transparency.

Issues related to spectrum auctions, infrastructure deployment, privacy, and 5G deployment. Issues related to National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).

Issues related to accelerated depreciation; Issues related to infrastructure deployment; Issues related to Research and Development Tax Credit; Issues related to Tax Cuts and Jobs Act (PL 115-97) Extension.

Issues related to corporate tax, net operating loss, EBITA/EBIDA.

Issues related to pharmacies, pharmacists, Medicare reimbursement, and opioids; Issues related to vaccines; Issues related to the FDA certification process; Issues related to Pharmacy Benefit Managers.

Issues related to pharmacies, pharmacists, and Medicare reimbursement; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Pharmacy Benefit Managers.

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Issues related to voter registration and voting; Issues related to H.R. 22/S. 128 - The SAVE Act.

Issues related to accelerated use of AMT credits; Issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to the Research and Development tax credit; Issues related to expensing.

Issues related to regulations that would restrict operations of farm bureau health insurance plans.

Issues related to education and advocacy pertaining to life science products and pipeline.

Issues related to hospital reimbursement.

Issues related to hospital reimbursement.

Issues related to Farm Bill Reauthorization; Issues related to the reintroduction of the Timber Innovation for Building Rural Communities Act (TIBRC) / 2026 Agriculture Appropriations; Issues related to Defense and Interior Appropriations; Issues related to extension of provisions in the Tax Cuts and Jobs Act (TCJA) (P.L. 115-97).

Issues related to Farm Bill Reauthorization; Issues related to the reintroduction of the Timber Innovation for Building Rural Communities Act (TIBRC) / 2026 Agriculture Appropriations; Issues related to Defense and Interior Appropriations; Issues related to extension of provisions in the Tax Cuts and Jobs Act (TCJA) (P.L. 115-97).

Issues related to international trade and tariff policies.

Issues related to safety standards for ROVs.

Issues related to the implementation of the 45X tax credit; Issues related to cybersecurity and enhanced energy infrastructure.

Issues related to the implementation of the 45X tax credit; Issues related to the One Big Beautiful Bill Act (P.L. 119-21).

Issues related to the implementation of the 45X tax credit; Issues related to the One Big Beautiful Bill Act (P.L. 119-21).

Issues related to orphan drug tax credit; Issues related to the excise tax for the Vaccine Injury Compensation Fund.

Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Drug pricing issues related to the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to flu and RSV vaccines.

Issues related to prescription drug pricing, including the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169); Issues related to Section 340B of the Public Health Service Act (P.L. 78-410); Issues related to pharmacy benefit managers.